Which has higher valuation & earnings, MREO or NGEN?

NervGen Pharma has lower revenue, but higher earnings than Mereo BioPharma Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group $500K 98.26 -$41.88M -$0.05 N/A NervGen Pharma N/A N/A N/A N/A N/A

Is MREO or NGEN more profitable?

NervGen Pharma's return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% NervGen Pharma N/A N/A N/A

Is MREO or OKUR more profitable?

OnKure Therapeutics' return on equity of -61.02% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% OnKure Therapeutics N/A -61.02% -55.99%

Which has preferable earnings & valuation, MREO or ADAG?

Adagene has higher revenue and earnings than Mereo BioPharma Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group $500K 98.26 -$41.88M -$0.05 N/A Adagene $7.67M 23.36 -$17.61M N/A N/A

Is MREO or ADAG more profitable?

Adagene's return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% Adagene N/A N/A N/A

Is TNYA or MREO more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% Mereo BioPharma Group N/A -81.28% -70.45%

Mereo BioPharma Group (MREO) Competitors

$0.31 -0.04 (-10.52%)

Closing price 04:00 PM Eastern

Extended Trading

$0.31 +0.00 (+1.04%)

As of 07:47 PM Eastern

Compare

MREO vs. NGEN, PLX, OKUR, ADAG, and TNYA

Should you buy Mereo BioPharma Group stock or one of its competitors? MarketBeat compares Mereo BioPharma Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mereo BioPharma Group include NervGen Pharma (NGEN), Protalix BioTherapeutics (PLX), OnKure Therapeutics (OKUR), Adagene (ADAG), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.

How does Mereo BioPharma Group compare to NervGen Pharma?

Mereo BioPharma Group (NASDAQ:MREO) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

NervGen Pharma's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
NervGen Pharma	N/A	N/A	N/A

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 955.88%. NervGen Pharma has a consensus price target of $18.00, indicating a potential upside of 827.84%. Given Mereo BioPharma Group's higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than NervGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NervGen Pharma has lower revenue, but higher earnings than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	98.26	-$41.88M	-$0.05	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, NervGen Pharma had 6 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 7 mentions for NervGen Pharma and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat NervGen Pharma's score of 0.49 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Very Positive
NervGen Pharma	Neutral

Summary

Mereo BioPharma Group beats NervGen Pharma on 6 of the 11 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

In the previous week, Protalix BioTherapeutics had 7 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for Protalix BioTherapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat Protalix BioTherapeutics' score of -0.50 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Negative
Mereo BioPharma Group	Very Positive

Protalix BioTherapeutics has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.17	$8.31M	$0.18	11.44
Mereo BioPharma Group	$500K	98.26	-$41.88M	-$0.05	N/A

Protalix BioTherapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mereo BioPharma Group has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 482.52%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 955.88%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Mereo BioPharma Group beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to OnKure Therapeutics?

Mereo BioPharma Group (NASDAQ:MREO) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Mereo BioPharma Group currently has a consensus target price of $3.25, suggesting a potential upside of 955.88%. OnKure Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 542.86%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mereo BioPharma Group has higher revenue and earnings than OnKure Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	98.26	-$41.88M	-$0.05	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

OnKure Therapeutics' return on equity of -61.02% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
OnKure Therapeutics	N/A	-61.02%	-55.99%

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, OnKure Therapeutics had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat OnKure Therapeutics' score of 0.44 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Very Positive
OnKure Therapeutics	Neutral

Summary

Mereo BioPharma Group beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Adagene?

Mereo BioPharma Group (NASDAQ:MREO) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Adagene has higher revenue and earnings than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	98.26	-$41.88M	-$0.05	N/A
Adagene	$7.67M	23.36	-$17.61M	N/A	N/A

In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 1 articles in the media. Adagene's average media sentiment score of 1.89 beat Mereo BioPharma Group's score of 1.87 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Very Positive
Adagene	Very Positive

Mereo BioPharma Group has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Mereo BioPharma Group presently has a consensus price target of $3.25, suggesting a potential upside of 955.88%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 111.64%. Given Mereo BioPharma Group's higher possible upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Adagene's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Adagene	N/A	N/A	N/A

Summary

Adagene beats Mereo BioPharma Group on 9 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Tenaya Therapeutics' return on equity of -80.56% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat Tenaya Therapeutics' score of 0.47 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Tenaya Therapeutics	Neutral
Mereo BioPharma Group	Very Positive

Tenaya Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Mereo BioPharma Group has higher revenue and earnings than Tenaya Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Mereo BioPharma Group	$500K	98.26	-$41.88M	-$0.05	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tenaya Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 359.77%. Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 955.88%. Given Mereo BioPharma Group's higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Tenaya Therapeutics beats Mereo BioPharma Group on 9 of the 15 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.91M	$3.40B	$6.43B	$12.56B
Dividend Yield	N/A	2.29%	2.69%	5.30%
P/E Ratio	-6.16	17.92	21.32	26.62
Price / Sales	98.26	334.54	551.43	114.14
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	1.18	6.84	9.95	6.88
Net Income	-$41.88M	$24.15M	$3.56B	$336.73M
7 Day Performance	10.60%	1.93%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	-85.62%	62.98%	36.32%	40.26%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.5463 of 5 stars	$0.31 -10.5%	$3.25 +955.9%	-83.9%	$54.91M	$500K	N/A	40	Positive News Gap Down
NGEN NervGen Pharma	3.5173 of 5 stars	$2.16 +3.8%	$18.00 +733.3%	N/A	$174.16M	N/A	N/A	N/A	Analyst Upgrade High Trading Volume
PLX Protalix BioTherapeutics	2.5875 of 5 stars	$2.16 +2.9%	$12.00 +455.6%	+36.1%	$174.04M	$76.38M	N/A	200
OKUR OnKure Therapeutics	2.9667 of 5 stars	$4.30 +2.1%	$27.00 +527.9%	+68.7%	$173.72M	N/A	N/A	N/A	Analyst Upgrade Short Interest Increase
ADAG Adagene	2.515 of 5 stars	$3.65 -2.7%	$8.00 +119.2%	+104.6%	$172.97M	$7.67M	N/A	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. NGEN, PLX, OKUR, ADAG, and TNYA

How does Mereo BioPharma Group compare to NervGen Pharma?

Summary

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Summary

How does Mereo BioPharma Group compare to OnKure Therapeutics?

Summary

How does Mereo BioPharma Group compare to Adagene?

Summary

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. NGEN, PLX, OKUR, ADAG, and TNYA

How does Mereo BioPharma Group compare to NervGen Pharma?

Is MREO or NGEN more profitable?

Do analysts recommend MREO or NGEN?

Do insiders and institutionals believe in MREO or NGEN?

Which has higher valuation & earnings, MREO or NGEN?

Does the media prefer MREO or NGEN?

Summary

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Does the media favor PLX or MREO?

Which has better valuation and earnings, PLX or MREO?

Which has more volatility and risk, PLX or MREO?

Do insiders & institutionals hold more shares of PLX or MREO?

Is PLX or MREO more profitable?

Do analysts prefer PLX or MREO?

Summary

How does Mereo BioPharma Group compare to OnKure Therapeutics?

Which has more volatility & risk, MREO or OKUR?

Do analysts prefer MREO or OKUR?

Which has stronger valuation & earnings, MREO or OKUR?

Is MREO or OKUR more profitable?

Do insiders & institutionals hold more shares of MREO or OKUR?

Does the media prefer MREO or OKUR?

Summary

How does Mereo BioPharma Group compare to Adagene?

Which has preferable earnings & valuation, MREO or ADAG?

Does the media prefer MREO or ADAG?

Which has more volatility and risk, MREO or ADAG?

Do analysts prefer MREO or ADAG?

Do insiders & institutionals believe in MREO or ADAG?

Is MREO or ADAG more profitable?

Summary

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Is TNYA or MREO more profitable?

Does the media prefer TNYA or MREO?

Which has more risk & volatility, TNYA or MREO?

Which has preferable earnings and valuation, TNYA or MREO?

Do institutionals and insiders have more ownership in TNYA or MREO?

Do analysts rate TNYA or MREO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools